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ABSTRACT 
Novel half-sandwich ruthenium(II) complexes with aminomethyl(diphenyl)phosphine derived 
from fluoroloquinolones (RuPCp, RuPSf, RuPLm, RuPNr) were being investigated as 
alternatives to well-established metal-based chemotherapeutics. All compounds were 
characterized by elemental analysis, selected spectroscopic methods (i.e., absorption and 
fluorescence spectroscopy, ESI-MS, NMR, circular dichroizm), X-ray diffractometry, ICP-
MS, and electrochemical techniques. To overcome low solubility, serious side effects 
connected with systemic cytotoxicity of ruthenium complexes, and acquiring the resistance of 
cancer cells, polymeric nanoformulations based on Pluronic P-123 micelles loaded with 
selected Ru(II) complexes were prepared and characterized. Resulting micelles (RuPCp_M, 
RuPNr_M) enabled efficient drug accumulation inside human lung adenocarcinoma (A549 
tumor cell line), proved by confocal microscopy and ICP-MS analysis, allowing cytotoxic 
action. Studied complexes exhibited promising cytotoxicity in vitro with IC50 values 
significantly lower than the reference drug cisplatin. The fluorescence spectroscopic data 
(CT-DNA titration, cell staining in vitro) together with analysis of DNA fragmentation 
  
(pBR322 plasmid, comet assay) provided clear evidence for the interaction with DNA 
inducing apoptotic cell death. 
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1. Introduction 
Despite the medicine and pharmacology development, cancer diseases are still one of the 
most often causes of death in the world. Among many of organic and inorganic compounds 
considered as potential chemotherapeutic agents, it is supposed that the metal complexes are 
ones of the most promising group. Their therapeutic potential in cancer therapy has recently 
attracted a lot of interest mainly because metals, in particular transition metals. They exhibit 
unique characteristics, such as redox activity, variable coordination modes and reactivity 
toward the organic substrates. For instance, the chemistry of ruthenium compounds has 
currently received intensive scrutiny, due to increasing interest in providing new alternatives 
to cisplatin. Ruthenium-based complexes have been developed not only because of promising 
cytotoxic anticancer properties but as well due to causing fewer and less severe side effects 
than the corresponding platinum(II) compounds. 
The discovery of therapeutic activity of (ImH)[trans-RuCl4(DMSO)Im] (NAMI-A) and 
(IndH)[trans-RuCl4(Ind)2] (KP1019) resulted in greater interest in the field of ruthenium 
complexes possessing prospective cytotoxic activity, including organometallic ruthenium(II) 
compounds [1-5]. At present, two classes of half sandwich η6-arene-Ru(II) complexes are of 
the most interest: (i) the monofunctional compounds, represented by [(η6-cym)Ru(en)Cl]PF6 
(cym = 1-methyl-4-(1-methylethyl)benzene, en = 1,2-ethylenediamine) and (ii) the 
bifunctional, represented by [((η6-cym))Ru(pta)Cl2] (pta = 1,3,5-triaza-7-phospha-tricyclo-
[3.3.1.1]decane), termed RAPTA-C. The first complex [(η6-cym)Ru(en)Cl](PF6) shows 
significant antitumor activity, comparable to that of carboplatin, towards various cancer cell 
lines in vitro. On the other hand, RAPTA-C exhibits low in vitro activity, while being active 
in vivo, inhibiting lung metastases in mice [6]. 
Furthermore, combination of two or even more multifunctional structural elements brings 
into play different properties of a compound and may result in improving the spectrum of 
biological activity, novel mechanisms of action, and modification of the pharmacokinetic 
  
profile of the drug [7, 8]. For instance, piano-stool Ru(II) compounds containing phosphines 
derived from fluoroquinolones can be prominent examples of this popular strategy of 
combining the structural elements, adopted currently in the design of new therapeutics. 
Quinolones are broad-spectrum antibiotics used in human and veterinary medicine for 
treatment of bacterial infections. What is noteworthy, quinolones also proved to cause 
immunomodulation and antitumor effects by different possible mode of action e.g., inhibition 
of the activity of HERG – one of the potassium channels, which are important proteins 
involved in the process of cancer cell proliferation [9]. Notably, quinolones are nowadays 
subject of many structural modification, including coordination compounds formation, aimed 
at not only defeat of increasing microbial resistance against antibiotics, but as well at potential 
alternatives to well-established anticancer chemotherapeutics. 
In our group we are focused on synthesis and characterization of metal complexes with 
phosphanes – a very interesting class of ligands with great capacity to structural modifications 
and tuning their physicochemical and, in consequence, biological properties. The majority of 
ruthenium(II) aminomethylphosphanes’ coordination compounds exhibited cytotoxicity in 
vitro against cancer cells close to cisplatin [10]. Moreover, the synthesized copper(I) and 
copper(II) complexes with phosphanes modified with quinolones (i.e., ciprofloxacin PCp, 
sparfloxacin PSf, lomefloxacin PLm, norfloxacin PNr) turned out to be more active than the 
parent antibiotics, and noteworthy possessed cytotoxicity in vitro towards selected cancer cell 
lines higher than cisplatin [11-14]. These findings encouraged us to implement quinolones’ 
phosphanes as well to half-sandwich ruthenium(II) complexes and investigate their 
prospective anticancer activity. 
Herein, we present the synthesis, physicochemical characterization, and preliminary 
biological study on anticancer activity in vitro evaluated towards lung adenocarcinoma of four 
novel piano-stool ruthenium(II) complexes. These organometallic complexes are an extension 
of the mono(aminomethyl)phosphane complex (RuPP1) reported recently [10], in which N-
ethylpiperazine ring was replaced by heterocyclic moieties of fluoroquinolones: ciprofloxacin 
(RuPCp), sparfloxacin (RuPSf), norfloxacin (RuPNr) and lomefloxacin (RuPLm) (Fig.1). 
  
 
Fig. 1. Schematic view of investigated “piano-stool” ruthenium(II) compounds with 
phosphanes derived from fluoroquinolones. 
 
 Effective uptake of metallodrugs, for instance ruthenium complexes, by cancer cells 
and normal cells is important factor for selective and effective cancer therapy. The high 
systemic cytotoxicity of chemotherapeutics, demonstrated by the uncontrolled destruction of 
normal cells, as well as the development of multidrug resistance, support the need to look for 
  
new effective targeted treatments based on nanotechnology and the changes in the molecular 
biology of the tumor cells. Thus, what is noteworthy, the main aim of this study was also to 
develop a new polymeric micellar formulation for effective ruthenium(II) complexes delivery, 
intended to be intravenously administered. To achieve this purpose, Pluronic P-123 (PEO20-
PPO70-PEO20) with longer hydrophobic blocks, was chosen mainly because of its commercial 
availability, biocompatibility and safety [15]. To the best of our knowledge, there are few 
reports on encapsulation of half-sandwich Ru(II) complexes into polymeric micelles [16-18]. 
The most advanced and innovative approach is presented by Su et al., who as the first 
proposed self-assembled polymer-based nanocarriers for delivery of ruthenium complexes for 
anticancer phototherapy. Photoresponsive Ru(II)-containing block copolymers release Ru(II) 
complex and 1O2 that both kill cancer cells [19-21]. 
2. Materials and methods 
2.1. Reagents 
All starting materials, including a 2nd (HCp, HNr, HLm) and 3rd (HSf) generation 
fluoroquinolones (>98%), [Ru(η6-p-cymene)Cl2]2 (1) (>98%), and Pluronic P-123 (PEO20-
PPO70-PEO20) were purchased from Sigma Aldrich and used as received. All syntheses were 
performed using standard Schlenk techniques. All solvents were deaerated prior to use. All 
obtained ruthenium complexes were dried under vacuum and increased temperature (40°C). 
Aminomethyl(diphenyl)phosphines: PSf (PPh2CH2Sf), PCp (PPh2CH2Cp), PLm 
(PPh2CH2Lm), and PNr (PPh2CH2Nr) were synthetized according to literature procedure 
described by our group elsewhere [22]. 
2.2. Structural characterization 
Single crystals of RuPCp∙CHCl3∙0.5CH3CN, 2RuPSf∙2CHCl3, RuPLm∙2CHCl3 and 
RuPNr∙2CHCl3 were collected on SuperNova diffractometer using graphite monochromatic 
MoKα radiation at 121 K , 126 K, 119 K or 130 K, respectively. Data processing was 
undertaken with CrysAlisPRO [23]. The structures were solved using direct methods and for 
refinement the non-H atoms were treated anisotropically. The main calculations were 
performed with SHELXL [24] and figures were plotted with MERCURY [25]. The crystal 
data, experimental details and refinement results are summarized in Table S1. 
Crystallographic data of the structures have been deposited at the Cambridge 
Crystallographic Data Centre with CCDC reference numbers CCDC 1814991 
(RuPCp∙CHCl3∙0.5CH3CN), CCDC 1814984 (2RuPSf∙2CHCl3), CCDC 1814964 
(RuPLm∙2CHCl3) and CCDC 1814944 (RuPNr∙2CHCl3). 
  
2.3. Elemental analysis, NMR, and ESI-MS analysis 
Elemental analyses (C, H and N) were carried out with Vario Micro Cube – Elementar. 
NMR spectra were recorded using Bruker Avance III 600 MHz and Bruker Avance II 300 
MHz spectrometers in CDCl3 with traces of CHCl3 as an internal reference for 1H and 
13C{1H}, and 85% H3PO4 in H2O as an external standard for 
31P{1H}. Mass spectra were 
collected with Bruker MicrOTOF-Q II spectrometer with ESI ion source in the following 
conditions: nebulizer pressure: 0.4 bar, dry gas: 4.0 l/min heated to 180°C. Data were 
recorded in the positive ion mode, while profile spectra were acquired in the mass range 50–
3000 m/z; end plate offset -500V; capillary voltage 4500V; mass resolving power of the 
instrument - over 18,000. Mass calibration was done using the cluster method with a mixture 
of 10 mM sodium formate and isopropanol (1:1, v/v) before run. In order to measure spectra 
the compounds were dissolved in chloroform. 
2.4. Synthesis and characterization of compounds 
RuPCp – [Ru(η6-p-cymene)Cl2PCp]. Binuclear ruthenium complex 1 (0.105 g, 0.171 mmol) 
was added to solution of PCp (0.200 g, 0.378 mmol) in dichloromethane (15 ml). Resulting 
mixture was stirred for 24 h. After that, it was evaporated to dryness giving solid red-orange 
residue of product. Yield: 80%. Anal. found: C, 51.81; H, 4.67; N, 4.43%. Anal. calc. for 
C40H43Cl2FN3O3PRu·CHCl3: C, 51.56; H, 4.64; N, 4.40%. NMR (298 K, CDCl3): 
1H: 0.88 
(H1, 3, d, 6.8 Hz, 6-H), 1.05-1.40 (H72, 73, m, 4-H), 1.84 (H10, s, 3-H), 2.28 (H13, 14, bs, 4-H), 
2.47 (H2, spt, 6.9 Hz, 1-H), 2.92 (H12, 15, bs, 4-H), 3.46 (H71, bs, 1-H), 3.89 (H11, s, 2-H), 5.13 
(H6, 8, d, 5.7 Hz, 2-H), 5.26 (H5, 9, d, 5.9 Hz, 2-H), 7.13 (H69, d, 7.1 Hz, 1-H), 7.41-7.62 
(H43, 44, m, 6-H), 7.89 (H63, d, 13.3 Hz, 1-H), 7.97-8.13 (H42, m, 4-H), 8.70 (H67, s, 1-H), 
14.99 (H70, s, 1-H); 31P{1H}: 27.0 (P1, s). +ESI-MS (CHCl3, m/z): 1695.3 (25.0%); 1673.3 
(8.73%) [2 RuPCp]+; 1277.4 (12.4%); 858.13 (43.0%) [RuPCp + Na – H]+; 836.15 (68.9%) 
[RuPCp]+; 800.17 (17.9%) [RuPCp – Cl – H]+; 574.16 (12.8%) [PCp + 2 Na]+; 552.18 
(100%) [PCp + Na]+. Crystals of RuPCp∙CHCl3∙1/2CH3CN suitable for X-ray analysis were 
obtained at fridge by slow evaporation of acetonitrile/chloroform (1:1, v/v) solution of in 
normal oxygen condition. Crystal data: C42H44Cl5FN3.5O3PRu, M = 974.1 g/mol, crystal size: 
0.20 × 0.15 × 0.05 mm, crystal system: triclinic, space group: ???, a = 12.2875(4) Å, b = 
12.3091(4) Å, c = 14.4938(4) Å, α = 93.860(3)°, β = 90.244(3)°, γ = 105.051(3)°, V = 
2111.62(12) Å3, Dcalc (Z = 2) = 1.532 g/cm
3, θ range for data collection: 2.995-28.550°, Mo 
Kα radiation (λ = 0.71073 Å), μMo = 0.774 mm-1, reflections collected/unique: 30334/9763, 
[Rint = 0.0340], completeness to θ full = 99.5%, final R indices [I > 2σ(I)]: R1 = 0.0376, wR2 
  
= 0.0912, R indices (all data): R1 = 0.0508, wR2 = 0.1002, GOF = 1.049, largest diff. peak and 
hole: 1.134 and -1.038 eÅ–3 , data/restraints/parameters: 9763/0/519, T = 121 K. 
RuPSf – [Ru(η6-p-cymene)Cl2PSf]. Following the method presented for RuPCp, 1 (0.094 g, 
0.153 mmol) and PSf (0.200 g, 0.339 mmol) gave red-orange precipitate. Yield: 80%. Anal. 
found: C, 50.57; H, 4.73; N, 5.51%. Anal. calc. for C42H47Cl2F2N4O3PRu·CHCl3: C, 50.82; H, 
4.76; N, 5.51%. NMR (298 K, CDCl3): 
1H: 0.89 (H16, 17, d, 6.7 Hz, 6-H), 0.96 (H1, 3, d, 7.0 Hz, 
6-H), 1.02-1.27 (H72, 73, m, 4-H), 1.78 (H10, s, 3-H), 2.29 (H12, 15, m, 2-H), 2.48 (H2, spt, 
7.0 Hz, 1-H), 2.76 (H13, 14, d, 10.9 Hz, 2-H), 2.95 (H13, 14, d, 11.2 Hz, 2-H), 3.85 (H71, m, 1-H), 
4.05 (H11, d, 2.9 Hz, 2-H), 5.15 (H5, 6, 8, 9, m, 4-H), 6.39 (H63, bs, 2-H), 7.40-7.60 (H43, 44, m, 6-
H), 7.98-8.17 (H42, m, 4-H), 8.60 (H67, s, 1-H), 14.61 (H70, s, 1-H); 31P{1H}: 25.7 (P1, s). 
+ESI-MS (CHCl3, m/z): 1104.8 (10.8%); 919.17 (12.0%) [RuPSf + Na]
+; 897.18 (19.1%) 
[RuPSf + H]+; 855.25 (33.5%) [RuPSf – cyclopropane]+; 824.74 (22.4%); 393.18 (100%) [Sf 
+ H]+. Crystals of 2RuPSf∙2CHCl3 suitable for X-ray analysis were obtained at fridge by slow 
diffusion of diethyl ether to solution of the complex in chloroform in normal oxygen 
condition. Crystal data: C86H96Cl10F4N8O6P2Ru2, M = 2032.3 g/mol, crystal size: 
0.20 × 0.10 × 0.03 mm, crystal system: triclinic, space group: ???, a = 13.7041(3) Å, b = 
16.8129(6) Å, c = 20.9633(6) Å, α = 71.016(3)°, β = 75.581(2)°, γ = 78.123(3)°, V = 
4382.2(2) Å3, Dcalc (Z = 2) = 1.540 g/cm
3, θ range for data collection: 2.841-28.601°, Mo Kα 
radiation (λ = 0.71073 Å), μMo = 0.752 mm-1, reflections collected/unique: 66135/20347, 
[Rint = 0.0724], completeness to θ full = 99.8%, final R indices [I > 2σ(I)]: R1 = 0.0628, wR2 
= 0.1429, R indices (all data): R1 = 0.1129, wR2 = 0.1759, GOF = 1.035, largest diff. peak and 
hole: 1.847 and -1.431 eÅ–3 , data/restraints/parameters: 20347/0/1087, T = 126 K. 
RuPLm – [Ru(η6-p-cymene)Cl2PLm]. Following the method presented for RuPCp, 1 
(0.101 g, 0.165 mmol) and PLm (0.200 g, 0.364 mmol) gave red-orange precipitate. Yield: 
80%. Anal. found: C, 56.27; H, 5.19; N, 4.88%. Anal. calc. for C40H44Cl2F2N3O3PRu: C, 
56.14; H, 5.18; N, 4.91%. NMR (298 K, CDCl3): 
1H: 0.67 (H16, d, 6.3 Hz, 3-H), 0.91 (H1, 3, d, 
6.9 Hz, 3-H), 0.99 (H1, 3, d, 6.9 Hz, 3-H), 1.49 (H72, t, 6.8 Hz, 3-H), 1.79 (H10, s, 3-H), 1.98-
3.10 (H12, 13, 14, 15, m, 7-H), 2.47 (H2, spt, 7.0 Hz, 1-H), 3.84-4.04 (H11, m, 2-H), 4.39 (H71, qd, 
J1 = 6.9 Hz, J2 = 3.3 Hz, 2-H), 5.03-5.28 (H
5, 6, 8, 9, m, 4-H), 7.40-7.60 (H43, 44, m, 6-H), 7.85 
(H63, dd, J1 = 12.0 Hz, J2 = 1.9 Hz, 1-H), 7.96-8.14 (H
42, m, 4-H), 8.54 (H67, s, 1-H), 14.67 
(H70, s, 1-H); 31P{1H}: 26.1 (P1, s). +ESI-MS (CHCl3, m/z): 878.14 (30.0%) [RuPLm + Na]
+; 
856.16 (100%) [RuPLm + H]+; 820.18 (84.8%) [RuPLm – Cl]+; 784.21 (9.64%) [2 (RuPLm 
– Cl – H)]2+; 572.19 (42.5%) [PLm + Na]+; 364.16 (15.2%) [CH2-Lm]+; 352.15 (9.78%) [Lm 
  
+ H]+; 328.94 (13.3%); 301.14 (22.3%). Crystals of RuPLm∙2CHCl3 suitable for X-ray 
analysis were obtained at fridge by slow evaporation of chloroform/toluene (1:3, v/v) solution 
of in normal oxygen condition. Crystal data: C42H46Cl8F2N3O3PRu, M = 1094.5 g/mol, crystal 
size: 0.39 × 0.13 × 0.12 mm, crystal system: monoclinic, space group: P21/n, a = 
29.2597(6) Å, b = 16.9010(3) Å, c = 9.8988(2) Å, α = 90°, β = 109.865(2)°, γ = 90°, V = 
4603.85(17) Å3, Dcalc (Z = 4) = 1.578 g/cm
3, θ range for data collection: 2.961-28.699°, Mo 
Kα radiation (λ = 0.71073 Å), μMo = 0.890 mm-1, reflections collected/unique: 65161/11131, 
[Rint = 0.0690], completeness to θ full = 99.7%, final R indices [I > 2σ(I)]: R1 = 0.0749, wR2 
= 0.1677, R indices (all data): R1 = 0.0959, wR2 = 0.1762, GOF = 1.188, largest diff. peak and 
hole: 1.160 and -0.707 eÅ–3 , data/restraints/parameters: 11131/0/558, T = 119 K. 
RuPNr – [Ru(η6-p-cymene)Cl2PNr]. Following the method presented for RuPCp, 1 
(0.108 g, 0.176 mmol) and PNr (0.200 g, 0.386 mmol) gave red-orange precipitate. Yield: 
80%. Anal. found: C, 56.99; H, 5.24; N, 5.07%. Anal. calc. for C39H43Cl2FN3O3PRu: C, 
56.87; H, 5.26; N, 5.10%. NMR (298 K, CDCl3): 
1H: 0.89 (H1, 3, d, 6.9 Hz, 6-H), 1.53 (H72, t, 
6.8 Hz, 3-H), 1.85 (H10, s, 3-H), 2.29 (H13, 14, bt, 4-H), 2.48 (H2, spt, 7.0 Hz, 1-H), 2.90 
(H12, 15, bt, 4-H), 3.89 (H11, s, 2-H), 4.23 (H71, q, 7.1 Hz, 2-H), 5.14 (H6, 8, d, 6.1 Hz, 2-H), 
5.26 (H5, 9, d, 5.9 Hz, 2-H), 6.61 (H69, d, 7.0 Hz, 1-H), 7.44-7.60 (H43, 44, m, 6-H), 7.97 (H63, 
d, 13.3 Hz, 1-H), 8.00-8.15 (H42, m, 4-H), 8.62 (H67, s, 1-H), 15.07 (H70, s, 1-H); 31P{1H}: 
26.9 (P1, s). +ESI-MS (CHCl3, m/z): 1058.16 (45.3%); 952.14 (19.1%); 923.17 (40.2%); 
824.15 (15.4%) [RuPNr + H]+; 788.18 (78.3%) [RuPNr – Cl]+; 752.20 (20.6%) [RuPNr – 2 
Cl – H]+; 564.09 (23.9%); 540.08 (45.4%); 511.60 (100%); 328.94 (22.1%); 255.58 (16.6%). 
Crystals of RuPCp∙2CHCl3 suitable for X-ray analysis were obtained at fridge by slow 
diffusion of hexane to solution of the complex in chloroform in normal oxygen condition. 
Crystal data: C41H45Cl8FN3O3PRu, M = 1062.4 g/mol, crystal size: 0.30 × 0.05 × 0.05 mm, 
crystal system: triclinic, space group: ???, a = 11.2574(2) Å, b = 14.6608(7) Å, c = 
15.7165(6) Å, α = 116.613(4)°, β = 95.054(2)°, γ = 95.231(3)°, V = 2285.07(16) Å3, Dcalc (Z 
= 2) = 1.544 g/cm3, θ range for data collection: 2.930-28.522°, Mo Kα radiation (λ = 
0.71073 Å), μMo = 0.891 mm-1, reflections collected/unique: 30595/10379, [Rint = 0.0485], 
completeness to θ full = 99.3%, final R indices [I > 2σ(I)]: R1 = 0.0671, wR2 = 0.1809, R 
indices (all data): R1 = 0.0886, wR2 = 0.2006, GOF = 1.047, largest diff. peak and hole: 3.013 
and -1.694 eÅ–3 , data/restraints/parameters: 10379/0/537, T = 130 K. 
 
 
  
2.5. Electrochemical characterization 
Cyclic voltammetry (CV) for 1 mM ruthenium(II) complexes was carried out on an 
electrochemical analyser (Bio-Logic, SP-150). Three-electrode glass cell with a working 
electrode – graphite disk electrode (2 mm diameter), a counter electrode – Pt wire, and a 
pseudo-reference electrode – Ag wire (Ag/Ag+, 0.01M AgNO3, 0.1M tetrabutyl ammonium 
perchlorate (Bu4NClO4). All measurements were done in dimethylformamide (DMF) with 
0.05M Bu4NClO4 as a supporting electrolyte at room temperature with scan rate 10 mV s
-1 in 
the potential range from -0.5 to 1.2V vs Ag/Ag+. Scans start at 0V vs Ag/Ag+ in the positive 
potential direction. All reported potentials were converted vs the ferrocene/ferrocenium redox 
couple (Fc0/+) [26]. 
2.6. Interactions with CT-DNA 
The stock solution of calf thymus DNA (CT-DNA) was prepared in 50 mM PBS 
(pH = 7.4). The concentration of CT-DNA was determined by spectrophotometer using molar 
absorption coefficient 6600 M-1 cm-1 at 260 nm. Stock solution was stored in a fridge and 
used for no longer than 4 days. Complex of CT-DNA and ethidium bromide (EB) was 
prepared by mixing the substrates in equimolar ratio (5∙10-5 M) with PBS. Fluorescence 
emission was recorded on spectrofluorimeter (Perkin Elmer LS55) at excitation wavelength 
equal to 510 nm, both emission and excitation slits widths were set to 5.0 nm. Kinetic assay 
was performed by fluorescence quenching of CT-DNA-EB complex by ruthenium 
compounds in 10-fold molar excess (i.e. molar ratio CT-DNA:EB:Ru was equal to 1:1:10). 
Appropriate aliquot of ruthenium complex solution in CHCl3 in fluorescence cuvette was 
evaporated. Then, 3 ml of CT-DNA-EB mixture was added to obtained thin-film of ruthenium 
compound and fluorescence was measured immediately. Stern-Volmer plots were obtained by 
titration CT-DNA-EB system with Ru complexes in molar ratios 1:1:1, 1:1:2, 1:1:5, 1:1:10 
and 1:1:20 (CT-DNA:EB:Ru) after 30 min incubation time. The emission and excitation slits 
widths were set to 5.0 nm. 
2.7. DNA strand break analysis 
In order to check the ability of RuPCp, RuPSf, RuPLm and RuPNr to induce single- or 
double-strand breaks in DNA the gel electrophoresis with pBR322 plasmid was performed. 
Compounds concentrations were equal to 100, 80, 60 and 40 μM in DMF. After 1h incubation 
time at 37°C, 20 μl reaction mixtures were mixed with 3 μl loading buffer (bromophenol blue 
in 30% glycerol) and loaded on 2% agarose gels (with EB) in TBE buffer (90 mM TRIS-
borate, 20 mM EDTA, pH = 8.0). Electrophoresis was conducted at constant voltage (115 V), 
  
for 3h. At the end gel was photographed and processed with Digital Imaging System 
(GelDocIt). 
2.8. Preparation of micelles 
In the round-bottom flask 0.25 g of Pluronic P-123 was dissolved in CHCl3 in 60°C, 
under reflux for 15 min. 1 ml of 0.5 mg/ml ruthenium compound and 1 ml of CHCl3 were 
added to hot solution and refluxed for 15 min. Solvent was slowly evaporated on rotary 
evaporator in 50°C and 500 mbar with speed rotation 270 rpm. Then, obtained thin film was 
dried under pressure reduced to 15 mbar for 15 min. Flask was transferred to sonication bath 
and 20 aliquots of 0.5 ml of PBS were added to film. Obtained solution was sonicated further 
for 15 min 0.1 ml of resulting solution was transferred to 0.9 ml of PBS in order to determine 
the size of the micelles. The rest of solution was centrifuged (5000 rpm, 15 min) and obtained 
residue was lyophilized. The supernatant was used to check the concentration of non-
encapsulated ruthenium complex utilizing ICP-MS technique (Perkin Elmer ELAN 6100). 
Drug loading content (LC) and encapsulation efficiency (EE) were calculated using equations: 
?? ? ?? ? ???? ? ????? 
?? ? ?? ????? ? ???? 
where: 
m0 – the starting mass of ruthenium complex before synthesis [g], 
m1 – the mass of ruthenium complex in supernatant after synthesis [g], 
mt – the total mass of micelles [g]. 
Micelles morphology was investigated with application of transmission electron microscopy 
(FEITM Tecnai G2 T20). Micelles were dropped in a carbon coated copper grid, dried at room 
temperature and stained with a negative staining agent (phosphotungstic acid). The size 
distribution was determined from the enlarged TEM micrographs, using ImageJ software, 
counting at least 200 particles in different images. The size were also examined by dynamic 
light scattering techniques (DLS, ZetaSizer Nano ZS, Malvern Instruments). 
2.9. Cell line 
A549 cell line (human lung adenocarcinoma, morphology: epithelial, ATCC: CCL-185) 
was cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Corning) with phenol red, 
supplemented with 10% fetal bovine serum (FBS) and with 1% streptomycin/penicillin. Cells 
were cultured at 37°C under a humidified atmosphere containing 5% CO2. Passages were 
  
carried out using a solution containing 0.05% trypsin and 0.5 mM EDTA. All experiments 
were performed on cells in the logarithmic phase of growth. 
2.10. Cytotoxic assay 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was 
performed according the protocols described elsewhere [27]. In brief, 1×104 cells per well 
were seeded in 96-well flat bottom microtiter plate and were incubated with the tested 
Pluronic P-123 micelles loaded with RuPCp or RuPNr complexes (RuPCp_M and 
RuPNr_M, respectively) at various range of concentrations (0.2-20 ?M) for 24 hours. After 
this, supernatants were pipetted out carefully and each well was washed with PBS. A further 
24 hours was allowed for the cells to recover in drug-free medium. Afterwards, cell viability 
was examined and IC50 was calculated using the Hill equation (Origin 9.0) with regard to the 
untreated cells (control). Each compound concentration was tested in five replicates and 
repeated at least three times. Determined values of IC50 are given as mean + S.D. (Standard 
Deviation). As well, cells after treatment were intravital stained with two commercially 
available dyes – acridine orange (AO, 5 mg/mL) and propidium iodide (PI, 5 mg/mL). Cells 
were incubated with dyes for 20 min in standard conditions, then dyes were removed, cells 
were washed with PBS twice, and examined using a fluorescence inverted microscope 
(Olympus IC51, Japan) with an excitation filter 470/20 nm. 
2.11. Cellular uptake 
A549 cells at density of 2×106 cells/2 mL were seeded on 6-well plates and were 
incubated with RuPCp_M and RuPNr_M formulations (2 μM) for 4 or 24h at standard 
conditions (37°C, 5% CO2). Additional plates were incubated with medium alone as negative 
control. Then, compound solutions were removed, the cells were washed twice with PBS 
buffer and trypsinized. The number of cells in each sample was counted manually and cells 
were centrifuged to obtain the whole cell pellet for analysis. For ICP-MS (inductively coupled 
plasma mass spectrometry) analysis cells were mineralized in 1 mL of 65% HNO3 at 60ºC for 
1 hour. Measurement of the concentration of ruthenium ions was carried out using a mass 
spectrometer (ELAN 6100 Perkin Elmer) with an inductively coupled plasma (ICP-MS). The 
copper content under each condition is expressed as ?g/ml Ru per 106 cells. The experiment 
was repeated at least 3 times and results are presented as mean value + S.D.. 
2.12. Confocal microscopy 
Confocal laser scanning microscopy (CLSM Nikon) was applied to visualize the 
intracellular accumulation of selected Pluronic P-123 Ru(II) complex formulation 
  
(RuPCp_M). In brief, A549 cells at a density of 5×105 cells/mL were seeded on coverslips in 
9-well plates and incubated for 24h allowing proper adhesion. Then, the growth medium was 
replaced with a medium containing 2 μM RuPCp_M and incubated for 4h at 37ºC in a 
humidified atmosphere containing 5% CO2. After this time, the cells were washed twice with 
PBS buffer and fixed by treating firstly with 2.5% glutaraldehyde in PBS and secondly with 
an increasing concentration gradient of ethanol (20, 40, 60, 80 and 99%). Samples were 
directly imaged under a Nikon A1 confocal laser scanning system (CM) attached to an 
inverted microscope Nikon Ti (Japan). A 1009 objective lens (Nikon Plan Apo VC/1.40 oil) 
was used. The samples were excited with diode lasers (405 and 488 nm). Fluorescence spectra 
were collected using a 32-channel spectral detector. 
2.13. Comet assay 
The level of DNA damage was determined by the electrophoresis of single cells in 
agarose gel as earlier described [13]. Briefly, the cell suspension was mixed with low melting 
point agarose, set on slides, lysed and neutralized in appropriate buffers. Electrophoresis was 
performed at 23V (0.74 V/cm, 300 mA) for 30 min at 4°C. All stages of the experiment were 
carried out in the dark to eliminate any extra DNA damages. Prior to analysis the slides were 
stained with propidium iodide (2.5 μg/ml). The analysis of DNA damage was carried out with 
COMET PLUS 2.9 software (Comet Plus, Theta System GmbH, Germany). The percentage 
content of DNA in the comet’s tail (%DNA) was determined from 100 random images of 
comets per slide. The analysis was done in three replicates. 
3. Results and discussion 
3.1. Structural characterization 
The products of syntheses were recrystallized in order to obtain pure complexes. Their 
purity were confirmed using elemental analysis, while the single crystals were analysed by X-
ray diffraction technique (Fig. 2, SI, Table S1). 
  
 
Fig. 2. Crystal structures of the complex molecules RuPCp, RuPNr, RuPLm, and RuPSf 
(30% probability ellipsoids). The solvents’ molecules and some hydrogen atoms were omitted 
for clarity. 
 
All obtained ruthenium complexes crystallized in ?? space group with one exception – 
RuPLm∙2CHCl3, which crystalized in ????? space group. What is noteworthy, in the case of 
2RuPSf·2CHCl3, both molecules of RuPSf in asymmetry unit adopt slightly different 
conformation (SI, Fig. S1), whereas, in the case of the other three complexes, there is only 
one molecule in the asymmetric unit. Coordination of phosphanes derived from 
fluoroquionolones did not cause significant changes in the ruthenium surrounding. Namely, 
only a slight increment in distance between Ru2+ ion and center of gravity of p-cymene ring 
(Cg) is observed (from 1.647 Å in parent dinuclear ruthenium(II) complex – 1 [10, 28], to 
about 1.707 Å - average distance for all complexes). Moreover, the length of Ru-Cl bonds 
decreased insignificantly from 2.444 Å to 2.416 Å (average for all complexes). The angle Cl-
Ru-Cg is higher in complexes comparing to dimeric ruthenium substrate of 2.7°. Mentioned 
changes in ruthenium(II) ion surrounding are very close to observed in time of RuPP1 
formation [10]. This suggests that extension of piperazine ring with heterocyclic moiety of 
fluoroquionolones do not affect the Ru-phosphane coordination significantly. 
The 31P{1H} NMR analysis, very useful method for preliminary determination of sample 
purity, was applied to verify if the product of synthesis is desired one (SI, Table S2). First of 
all, the signal of uncoordinated aminomethylphosphane is situated in the negative part of 
  
spectrum (PCp: ?27.4 ppm; PSf: ?35.9 ppm; PLm: ?27.4 ppm; PNr: ?27.5 ppm) and 
undergoes a downfield shift to the positive part of spectrum as a result of phosphane 
coordination (RuPCp: 27.0 ppm; RuPSf: 25.7 ppm; RuPLm 26.1 ppm; RuPNr: 26.9 ppm). 
Absence of other signals in spectrum confirms that coordination compound is the only one 
product of synthesis, free from phosphane derivatives (e.g., phosphane oxides). Secondly, 1H 
NMR measurement evidenced that phosphane coordination does not affect significantly 
density of electron in fluoroquinolone part. The heterocycle protons’ signals are shifted less 
than 0.21 ppm comparing to uncoordinated phosphane. Formation of bond between ruthenium 
and fluoroquinolone phosphane induces the changes in 1H NMR spectrum of cymene close to 
these observed in time of RuPP1 formation. Namely, H
1-H10 undergoes upfield shift 
independently of the type of substituent bonded to piperazine ring. The isopropyl H1 and H3 
protons are equivalent and observed as doublet in spectra of RuPCp, RuPSf and RuPNr, but 
interestingly not in the case of RuPLm. In spectrum of this complex the methyl groups 
appear as two separated doublets. This suggests that rotation of isopropyl group in RuPLm is 
inhibited. 
Furthermore, mass spectrometry results confirmed the structures of prepared coordination 
compounds. The complexes were ionized within chloride detaching, H+ or Na+ connection or 
ruthenium oxidation. Generally, RuPCp, RuPSf, RuPLm and RuPNr turned out to be 
susceptible to fragmentation in measurement condition, therefore plenty of signals were 
observed in complexes’ spectra, what made obtained spectra difficult for unambiguously 
interpretation (SI, Fig. S2-S5). 
It is well-documented in literature, that replacement of the chloride by a DNA fragment 
in the coordination sphere of the metal results in formation a covalent bonds between them, 
what accounts for the cytotoxicity of organoruthenium species [29-31]. In the case of 
complexes with the general formula [(η6-arene)Ru(L)Cl2] (L = ligand) aquation seems to be 
important step in cytotoxicity, producing the ruthenium active site in order to react with 
biomacromolecules i.e., proteins, DNA. The RuPCp, RuPSf, RuPLm, and RuPNr, similar 
to previously published RuPP1, in controlled condition are hydrolysed very slowly [10]. 
Nevertheless, in cellular environment there is a plethora of electron-donating species and in 
such conditions the substitution of any ligand cannot be excluded. Furthermore, it is well-
known that hydrolysis, that is suppressed extracellularly, due to the high chloride 
concentration (104 mM), it occurs inside the cell, in cytoplasm or the nucleus, where the 
chloride concentration is significantly lower [6]. Thus, presumably, the studied complexes 
  
will hydrolyze relatively very slowly inside tumor cells, reaching the equilibrium with an 
amount of the complex remaining non-hydrolyzed. Indeed, both hydrolyzed and non-
hydrolyzed complexes are able to interact with DNA (directly or through its ligands, 
respectively), thereby causing significant alterations to DNA structure. Importantly, also the 
non-hydrolyzed forms of RuPCp, RuPSf, RuPLm and RuPNr are able to interact with DNA 
(through fluoroquinolones or arene), therefore presumably the hydrolysis may not be the 
crucial process in case of synthesized complexes. 
3.2. Electrochemical characterization 
The reactivity of metal-based drugs depends largely on their ligand environment and 
coordination geometry, which is also determined the redox properties. The knowledge of 
metal-centered redox potentials can provide an essential information for the design of new 
complexes and a better understanding of the role of metallodrugs in biological applications. 
The electrochemical properties of ruthenium(II) complexes were investigated in order to 
assess and understand their potential role in cellular signaling through redox chemistry. Any 
disturbances of intracellular redox processes may significantly influences on a plethora of 
cellular processes such as right proliferation. This may, in turn, result in serious consequences 
including cell death [32]. 
The redox properties of new Ru(II) complexes and the corresponding ligands alone were 
determined by cyclic voltammetry in dimethylformamide (DMF) solutions (1 mM) using 
0.1 M tetrabutyl ammonium perchlorate (TBAP) as the supporting electrolyte in the selected 
potential window from -0.5 V to 1.2 V vs Ag/Ag+ at a scan rate of 10 mV/s. The cyclic 
voltammetric responses obtained for all studied complexes with apparent oxidation peaks 
localized at ca. 0.6 V and 0.9 V vs Fc0/+ are presented in Fig. 3. 
  
 
Fig. 3. Cyclic voltammograms of RuPCp, RuPSpf, RuPLm, and RuPNr ruthenium(II) 
complexes in DMF (1 mM). Scan rate: 10 mV/s. The potentials were referenced to the Fc0/+ 
redox couple. 
 
All the complexes displayed irreversible one-electron redox waves which can be 
attributed to Ru(II) ion oxidation at ca. 0.6 V vs Fc0/+. The determined oxidation potentials for 
studied ruthenium(II) complexes, referring to Ru(II)/(III) redox process, are in agreement with 
literature data for other organometallic Ru(II) compounds [30, 33, 34]. Additional peaks, 
observed in cyclic voltammograms of studied complexes, can be safely associated with 
oxidation processes within ligand moiety on comparing with the electrochemical data of 
ligands alone (SI, Fig. S7). From the electrochemical data, it can be concluded that the 
present ligand systems in form of aminomethylophoshine derivatives of antibiotics do not 
stabilize the oxidation state of ruthenium(II) ion. This means, that the investigated 
complexes are not electrochemically stable, suggested by observed some instability of the 
oxidized ruthenium species at the electrode surface. However, it can be presumed that the 
electron transfer reactions take place without gross changes in the stereochemistry of the 
  
complexes, that can be monitored by UV-vis spectroscopy. In UV-vis spectra no 
significant changes were observed, indicating the formation of completely new chemical 
compounds, as only decrease in absorption were detected after electrochemical study (SI, 
Fig. S8). What is also noteworthy, monitored changes in UV-vis spectra during 24 hours 
in DMF solvent did not revealed spectral changes implicating ligands exchange due to 
DMF coordination (SI, Fig. S9). Thus, even though it is stated that Ru(II) arene “piano-
stool” complexes are normally unable to change their +II oxidation state due to stabilization 
by the ?-bonded arene ligands [35], the studied organometallic complexes with 
aminomethyl(diphenyl)phosphanes of fluoroquinolones are prone to undergo electrochemical 
processes. Taking into consideration the potential values for oxidation of Ru(II) ion it can be 
supposed that investigated complexes can participate in redox chemistry inside cells, as the 
required redox potential window is estimated to be −0.4 to +0.8 V vs NHE [36]. This may 
result in strengthening the production of reactive oxygen species and in consequence lead to 
irreversible changes in cellular redox equilibrium, that end in cell death. 
3.3. Interactions with CT-DNA 
Knowing that DNA is a potential target for transition metal anticancer complexes [6, 37, 
38], we investigated the binding profiles of studied ruthenium(II) complexes to calf thymus 
DNA (CT-DNA) in order to provide insight into their mechanism of action. Fluorescence 
spectroscopy was used to study kinetics of interactions between CT-DNA and studied 
ruthenium(II) complexes. To achieve this, the fluorescence spectra of complexes in the 
absence and presence of CT-DNA at different concentrations were recorded. Stern-Volmer 
plots, obtained by titration of CT-DNA-EB system with Ru(II) complexes in molar ratios 
1:1:1, 1:1:2, 1:1:5, 1:1:10 and 1:1:20 (CT-DNA:EB:Ru) after 1 hour incubation time, are 
presented in Fig. 4. 
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Fig. 4. Stern–Volmer plots of the CT DNA–EB system quenched by (A) PCp, PSf, PLm, 
PNr, and (B) RuPCp, RuPSf, RuPLm, RuPNr. I0 and I – intensity of CT DNA–EB in the 
absence and presence of the increasing concentration of the compounds [?M]. 
 
Upon addition of CT-DNA to ligands or the corresponding Ru(II) complexes, a 
considerable decrease in fluorescence was observed without significant changes in the 
wavelength of CT transition for complexes. Stern-Volmer plots for all of the phosphanes 
(PCp, PSf, PLm, and PNr), and ruthenium(II) complexes (RuPCp, RuPSf, RuPLm, 
RuPNr) are linear, what proves dynamic mechanism of interactions between DNA and 
studied compounds and confirms their intercalating properties. Observed fluorescence 
quenching of CT-DNA-EB complex clearly indicates that new studied “piano-stool” 
ruthenium(II) compounds are able to intercalate between DNA base pairs. Ru(II) complexes 
are more effective intercalators than the corresponding phosphines due to lower values of I/I0 
at the end of incubation time (SI, Fig. S10) and higher values of slope factors of Stern–
Volmer dependencies (Fig. 4). The strength of the ligands’ and complexes’ intercalation with 
CT-DNA, expressed by Ksv values, is shown in Table 1. 
 
 
 
 
 
 
  
Table 1 
Determined Ksv values for the studied phosphanes and studied Ru(II) complexes. 
KSV [M
?1] 
PCp 7.62 × 101 RuPCp 1.34 × 103 
PSf 2.05 × 102 RuPSf 1.60 × 103 
PLm 2.59 × 102 RuPLm 1.07 × 103 
PNr 5.27 × 102 RuPNr 6.32 × 102 
 
Interestingly, in-depth analysis of Stern–Volmer plots leads to conclusion, that from the 
point of view of more efficient interactions with CT-DNA, the presence of the cyclopropane 
substituent in the antibiotic structure of coordinated phosphine ligand plays a crucial role. 
This conclusion is drawn based on Ksv values, which are 1.34 × 10
3 M?1 and 6.32 × 102 M?1 
for RuPCp and RuPNr, respectively. The same dependence of values was observed for the 
corresponding phosphines (vide supra, Table 1). Whereas, substituents in piperazine structure 
did not influence intercalation properties of studied half-sandwich Ru(II) complexes modified 
with phosphane derivatives of fluoroquinolones, as there are not significant difference in Ksv 
values for PSf and PLm ligands, as well as for RuPSf and RuPLm complexes (vide supra, 
Table 1, Fig 1). 
Moreover, circular dichroism (CD) spectroscopy demonstrated that the investigated 
RuPCp, RuPSf, RuPLm, RuPNr complexes did not cause the conformational changes in 
CT-DNA structure. After CT-DNA titration by Ru(II) complexes no noticeable changes in 
CD spectra were observed (SI, Fig. S11), indicating binding to DNA by coordination or 
destruction its superhelical conformation, in similarity to the corresponding phosphanes 
(PCp, PSf, PLm, and PNr) [11]. These findings suggest intercalation or surface interaction 
involving π-stacking interactions between the complex and the DNA base pair. 
3.4. pBR322 plasmid damage 
In order to get more information on a direct DNA–metal interaction of studied 
ruthenium(II) complexes we decided to study the alteration of DNA structure by the 
electrophoretic mobility of different forms of DNA plasmid on agarose gels (Fig. 5). 
  
 
Fig. 5. Selected agarose gel electrophoresis of pBR322 plasmid cleavage by half sandwich 
ruthenium(II) complex with aminomethylphosphines derived from ciprofloxacine in the 10% 
DMF solution. Lanes: 1 – plasmid (control); 2 – plasmid + 60 μM RuPCp; 3 – plasmid + 
80 μM RuPCp; 4 – plasmid + 100 μM RuPCp. 
 
When pBR322 plasmid was incubated with increasing concentrations of RuPCp an 
increase of the relaxed open circular form of the plasmid (form II) was observed, that was 
found to correlate inversely with the amount of the supercoiled form (form I). This clearly 
indicates that since a direct conversion of the form I into the form II is taking place, thus the 
studied complexes are able to cause a single-strain plasmid cleavage. It can also be supposed 
that investigated complexes are not capable of a double-strain plasmid damage leading to 
formation of a linear form of the plasmid (form III), which is not observed in the gel 
electrophoresis of pBR322 plasmid (Fig. 5). It is worth mentioning that the corresponding 
ligands alone (PCp, PSf, PLm, and PNr), even though they exhibited slight interactions with 
CT-DNA (vide supra, Fig. 4), did not cause any DNA degradation [11]. Our findings are in 
agreement with work of Romerosa et al., who also observed formation of open circular form 
of plasmid resulting from not selective interactions of cyclopentadienidoruthenium(II) 
complexes bearing water-soluble phosphanes with nucleobases within intra- or inter-strand 
crosslinking. The authors suggested that piano-stool Ru(II) complexes can be active DNA 
agents acting by both mechanisms – with or without phosphine ligand dissociation (non-
dissociative or dissociative mechanism, respectively) [29]. 
3.5. Polymeric micelles 
The emergence of selective and efficient delivery of highly hydrophobic drugs into living 
system has intensified the need for their encapsulation inside drug delivery systems, for 
instance polymeric micelles, liposomes, and other more sophisticated supramolecular 
assemblies [15, 39-42]. The versatility of polymeric micelles produced from amphiphilic 
copolymers offers variety of self-assembled nanostructures with diverse morphology and size 
  
in the range between 10 to 200 nm [39]. This results in significant advances in biomedical 
area due to their varying functions and clinical applications. Furthermore, this strategy 
enables to reduce systemic toxicity by enhancing passive accumulation in the tumor tissue due 
to the enhanced permeability and retention (EPR) effect [43-45]. 
Furthermore, since most of the ruthenium(II) complexes are not sufficiently soluble in 
water, therefore DMSO or DMF has to be usually used as solubilizing agent. However, this 
often leads to the solvolysis of the ruthenium(II) complexes, as shown recently for instance 
for [Ru(η6-arene)Cl2(L)] complexes (L = N-heterocyclic ligands) [46]. In consequence, 
solvolised ruthenium(II) complex may exhibit totally different activity in vitro in comparison 
to a parent dichlorido compound. In the case of the half-sandwich ruthenium(II) complex 
RuPP1, studied by us previously and treated as the parent complex, we observed that this 
complex was susceptible to decomposition [10]. Thus, in order to avoid solvolysis of metal 
complexes various delivery systems such as mentioned above formulations loaded with these 
complexes have been currently proposed. Concluding, justification of application of drug 
delivery systems for highly active anticancer compounds lies not only in prevention of 
hydrolysis or solvolysis, but also in precise accumulation in the target tumor tissue, drug 
release, and selective local application [8]. 
Accordingly to all above-mentioned and due to poor solubility of studied ruthenium(II) 
complexes in water we decided to encapsulate two complexes (RuPCp and RuPNr) into 
polymeric micelles made of Pluronic P-123 (PEO-PPO-PEO triblock copolymer), using thin-
film hydration method [47]. RuPCp and RuPNr were selected consciously because of 
differences in the structure of coordinated fluoroquinolones (cyclopropyl and ethyl moiety in 
quinolone, respectively). This presumably resulted in the strongest and the weakest interaction 
with CT-DNA for RuPCp and RuPNr, respectively (vide supra, Fig. 4). Apparently, these 
complexes should also exhibit different biological activity in vitro. TEM images of selected 
Pluronic P-123 micelles with encapsulated RuPNr complex (RuPNr_M) with statistical 
analysis of size (ImageJ) are presented in Fig. 6. 
  
 
Fig. 6. TEM images of Pluronic P-123 formulation with encapsulated RuPNr complex 
(RuPNr_M) with statistical analysis of size (ImageJ). 
 
Negative staining TEM images revealed spherical shape and smooth surface forming 
homogeneous polymeric micelles with a size in agreement with DLS data (Table 2). 
Table 2 
Hydrodynamic diameter determined by DLS technique, loading content and encapsulation 
efficiency for selected Pluronic P-123 formulation. 
formulation hydrodynamic diameter [nm] LC ± S.D. [%] EE ± S.D. [%] 
P-123_M 22 ± 8 
PDI 0.5 ± 0.1 
- - 
RuPCp_M 26 ± 5 
PDI 0.4 ± 0.1 
3.9 ± 3.1 96.3 ± 1.5 
RuPNr_M 26 ± 3 
PDI 0.4 ± 0.1 
9.3 ± 3.5 94.0 ± 0.2 
 
Drug loading content (LC) and encapsulation efficiency (EE) were assessed with 
application of ICP-MS technique (Table 2). In the case of both studied complexes the 
determined LC and EE values prove effective and efficient loading of the Ru(II) complexes 
inside the Pluronic P-123 micelles, what will ensure their effective delivery. The mean 
micelle size of RuPCp_M and RuPNr_M was less than 50 nm, which is smaller than the 
critical size required to avoid capture by the reticuloendothelial system (RES). In view of the 
  
determined small size of the Pluronic P-123 micelles loaded with RuPCp or RuPNr 
complexes (ca. 25 nm), it is plausible that such nanoformulations will facilitate ruthenium(II) 
complexes accumulation into tumor tissues combining the avoidance of the RES system with 
the EPR effect and low steric hindrance. Zeta potential of stable RuPNr_M micelles was 
equal to be??1.59 ± 0.33 mV (pH = 7.4), resulting from slightly negative potential of 
uncharged PEO amphiphilic copolymers [48]. Given low value indicates the tendency to 
aggregation of synthesized micelles, what is beneficial for accelerating of drug release. As the 
polymeric micelles enter the tumor cells (vide infra, Fig. 8 and 9), it can be supposed that in 
pathological tumor microenvironment, characterized by lower pH (e.g., pH = 5.5 for 
endosome, pH = 5.0 for lysosome), when compared with normal tissues (pH = 7.4), efficient 
release of Ru(II) complexes will be facilitated. This will be realized mainly due to the fact that 
such Pluronic P-123 nanoformulations tend to form aggregates releasing their load in 
dependence to pH, as observed also by other authors [47]. 
3.6. Cytotoxicity study in vitro 
Herein, the cytotoxicity of two particular polymeric formulations RuPCp_M and 
RuPNr_M was studied on selected cell line – an lung adenocarcinoma cells (A549 cell line). 
The cell viability was assessed by MTT assay after 24 hours incubation with studied 
formulations and additional 24h for recovery time in free media (Table 3). 
Table 3 
IC50 values [?M] for A549 cell line determined after 24h incubation with RuPCp_M and 
RuPNr_M and additional 24h for recovery time in free media. 
A549 cell line (24h) 
formulation IC50 ± SD [?M] 
RuPCp_M 39.5 ± 9.3 
RuPNr_M 77.1 ± 2.7 
 
As shown in Table 3, both RuPCp_M and RuPNr_M exhibited high cytotoxicity 
towards studied human cancer cells, when compared with the earlier studied by our group 
organometallic ruthenium(II) complexes with aminomethylphospanes derived from 
morpholine or piperazine and not bearing fluoroquinolones’ moieties. What is noteworthy, the 
determined IC50 values are one order of magnitude higher than in the case of the latter 
complexes and cisplatin [10]. Notably, RuPCp_M displayed higher cytotoxicity than 
  
RuPNr_M in vitro, what corresponds to their higher affinity of the DNA-binding showed in 
the model study on CT-DNA interactions (vide supra, Fig 4). 
Cellular morphology after treatment with studied micelles was visualized via microscopy, 
including fluorescent imaging after adequate dye staining with acridine orange (AO) and 
propidium iodide (PI) (Fig. 7). 
 
Fig. 7. Visible light and fluorescent images presenting A549 cells: (A, C) untreated (control) 
and (B, D) treated with RuPCp_M formulation for 24 hours at IC50 concentration. Cells after 
treatment were stained with acridine orange (green, viable cells) and propidium iodide (red, 
dead cells). Bar – 50 μm 
 
AO is a vital dye, which stains both live and dead cells, while PI stains only cells that 
have lost membrane integrity. Analysis of fluorescence images revealed significant changes in 
cell morphology, indicating number of viable (green, AO+) and dead (red, PI+) cells. While, 
untreated control cells appeared uniformly green with spindle-shape. 
3.7. Cellular uptake 
  
One of the major goals in the development of novel metal-based anticancer drug 
candidates is to obtain an efficient uptake of a compound into tumor cells, while presenting 
increased therapeutic efficacy and decreased cytotoxicity in the case of healthy tissue. 
Confocal microscopy was applied to confirm cellular uptake of studied RuPCp_M and 
RuPNr_M formulations (Fig. 8).  
 
Fig. 8. Confocal microscopy. (A) and (B) selected 3D images of A549 cells after 4h 
incubation with RuPCp_M at IC50 in different positions (magnification 60.00×, 
ex = 358 nm), (C) cross-sectional image, and (D) emission spectra of cells after treatment and 
control cells (untreated A549 cells). 
 
Confocal microscopy confirms unquestionably cellular uptake of RuPCp_M and 
RuPNr_M formulations. This is proved by analysis of the cross-sectional images and 
emission spectra of the tested compounds, that penetrated into the cells. Non-differing in 
intensity emission from the compounds was visible inside the whole cell, what indicates their 
uniform distribution throughout the cells and no favorable accumulation in any cellular 
compartments or organelles. 
  
Furthermore, to assess how efficiently micelles loaded with ruthenium(II) compounds 
were taken up by A549 cells, the cellular accumulation of Ru ion was detected using ICP-MS 
technique after cell treatment with 2 ?? RuPCp_M or RuPNr_M for 4 and 24 hours 
(Fig. 9). 
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Fig. 9. Intracellular ruthenium accumulation expressed by ?g/ml Ru per 106 cells after 4 and 
24 hours of A549 cell incubation with 2 ?? RuPCp_M or RuPNr_M. 
 
Time-depending cellular uptake of RuPCp_M and RuPNr_M was determined to be 
0.77 ± 0.21 ?g/ml Ru/106 cells and 0.72 ± 0.17 ?g/ml Ru/106 cells, respectively following 
long-term treatment (24h). This indicates significantly increased accumulation of Ru(II) 
complexes, when compared with studied previously counterparts with aminomethylphospanes 
derived from piperazine not bearing fluoroquinolone’s motif, as reported previously [10]. 
These results, together with confocal analysis, clearly support an enhanced pattern of cellular 
uptake into A549 cells of micellar nanocarriers containing the studied organometallic 
ruthenium(II) complexes. It can be concluded that successful and efficient uptake of poorly 
soluble half-sandwich Ru(II) complexes is observed mainly because of the interesting feature 
of Pluronic P-123, which is capable to interact with cell membranes, leading to decreased 
microviscosity, pore formation on the membrane and accelerated transmembrane drug 
translocation [47]. 
  
3.8. Comet assay 
Several mechanisms have been proposed to elucidate the anticancer activities of 
ruthenium complexes: (i) interaction with DNA, (ii) blocking of the cell cycle, (iii) inhibition 
of various kinases, (iv) inhibition of topoisomerases, and (v) induction of mitochondrial 
dysfunction pathway [1]. To gain more insight into the underlying mechanism of cytotoxicity 
induced by nanoformulation containing selected Ru(II) complex (RuPCp_M), induction of 
DNA damage, which is considered as hallmark of apoptosis, was investigated. The single-cell 
gel electrophoresis (comet assay) is an effective and simple measure for evaluating the DNA 
integrity, since a cell with damaged DNA stained with EB, subjected to electrophoresis, 
appears as a comet like. 
 
Fig. 10. Comet assay analysis of DNA damage. Representative images of (A) A549 untreated 
cells (control) and (B) cells after 24h treatment with RuPCp_M formulation (20 ?M 
RuPCp). (C) DNA damage presented as the mean value of the percentage of DNA in the 
comet tail (DNA in tail %) with increasing concentration of RuPCp. Given concentrations 
refers to RuPCp complex encapsulated inside micelles. Images were made using the 
computer program Comet Plus (Theta System GmbH, Germany). 
  
 
As shown in Fig. 10 in the control (untreated cells), the percentage of DNA in the comet 
tail was found to be at ca. 8%. After the treatment of A549 cells with the increasing 
concentration of RuPCp complex for 24 hours (introduced into cells in RuPCp_M), the 
statistically significant and well-formed comet like was observed. The length of tail indicated 
the extent of ca. 26% of DNA damage. These results identify the studied complex can lead to 
DNA damage in A549 cells, which is an undoubted hallmark of apoptotic cell death, mitotic 
catastrophe or both [49]. Importantly, based on these findings along with, in particular, 
interactions with CT-DNA and pBR322 plasmid (intercalating properties, cleavage of DNA 
helix), it can be supposed that studied arene Ru(II) complexes arrest cells for DNA repair 
resulting in irreversible DNA damage and subsequent cell death. It is well-known that DNA 
damage can be caused not only by direct interactions of chemotherapeutics with nucleic acid 
double helix but also by other mechanisms such as ROS-mediated DNA cleavage. First of all, 
our research shows that the mechanism associated with the generation of ROS can not be 
rejected. In addition, other molecular pathways affecting the increase of DNA damage such as 
mitochondrial activation of apoptosis should also be taken into account. Thus, more precise 
investigation focused on elucidation of molecular mode of action of studied piano-stool 
ruthenium(II) complexes with phosphane derivatives of fluoroquinolones is required. 
4. Conclusions 
In this paper, we explored the potential of Pluronic P-123 micelles as suitable 
nanocarriers to deliver two selected ruthenium(II) compounds RuPCp and RuPNr, allowing 
to maintain their activity and mechanism of action. Studied functionalities such as micelle 
stability, micellar size distribution, drug loading capacity, and high cytotoxic index towards 
cancer cells provide with possible application of these polymeric nanosystems for selective 
and efficient delivery of anticancer drugs i.e., organometallic Ru(II) complexes with 
phosphine derivatives of fluoroquinolones. What is noteworthy, determined small size of 
prepared micelles (ca. 25 nm) and high drug loading efficiency (ca. 95%) ideally meets 
crucial design criteria for an effective penetration into the tissue (proved by confocal 
microscopy). Presumably, this will provide stealth against mononuclear phagocyte system 
(MPS) for sufficient longer circulation and better accumulation in the target tissue. 
Importantly, based on electrochemical characterization of all studied complexes we postulate 
their participation in intracellular redox processes connected with ROS generation. 
Furthermore, study on interactions with macromolecules (CT-DNA, pBR322 plasmid) 
  
revealed: (i) intercalating properties of investigated arene Ru(II) complexes, and (ii) 
possibility to induce a single strand DNA cleavage. Irreversible DNA fragmentation was also 
confirmed by single cell gel electrophoresis (comet assay) in an agarose gel matrix. In light of 
these results it may be supposed that prepared FDA-proved polymeric nanoformulations 
containing arene Ru(II) complexes with aminomethyl(diphenyl)phosphine derived from 
fluoroloquinolones will assure safe biodegradability for easy elimination from the body, 
targetability for therapeutic efficacy, tunable stability, improved pharmacokinetics and 
pharmacodynamic profiles. Finally, reproducibility along with facile and inexpensive method 
of synthesis will be also guaranteed. 
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Table S1. Crystallographic experimental details. 
Parameters RuPCp∙CHCl3∙0.5CH3CN 2RuPSf∙2CHCl3 RuPLm∙2CHCl3 RuPNr∙2CHCl3 
Moiety formula RuCl5FPN3.5O3C42H44 Ru2Cl10F4P2N8O6C86H96 RuCl8F2PN3O3C42H46 RuCl8FPN3O3C41H45 
Formula weight (g∙mol-1) 974.1 2032.3 1094.5 1062.4 
Crystal size (mm) 0.20 x 0.15 x 0.05  0.20 x 0.10 x 0.03 0.39 x 0.13 x 0.12 0.30 x 0.05 x 0.05 
Temperature (K) 121 126 119 130 
Type of radiation Mo Kα Mo Kα Mo Kα Mo Kα 
Crystal system Triclinic Triclinic Monoclinic Triclinic 
Space group P ?? P ?? P 21/n P ?? 
Unit cel dimensions 
a (Å) 12.2875(4) 13.7041(3) 29.2597(6) 11.2574(2) 
b (Å) 12.3091(4) 16.8129(6) 16.9010(3) 14.6608(7) 
c (Å) 14.4938(4) 20.9633(6) 9.8988(2) 15.7165(6) 
α (°) 93.860(3) 71.016(3) 90 116.613(4) 
β (°) 90.244(3) 75.581(2) 109.865(2)° 95.054(2) 
γ (°) 105.051(3) 78.123(3) 90 95.231(3) 
Volume (Å3) 2111.62(12) 4382.2(2) 4603.85(17) 2285.07(16) 
Z 2 2 4 2 
Density calc. (g/ cm3) 1.532 1.540 1.578 1.544 
Absorption coeff. (mm
-1
) 0.774 0.752 0.890 0.891 
F(000) 995 2080 2220 1080 
θmin – θmax (°) 2.9954 to 28.550 2.841 to 28.601 2.961 to 28.699 2.930 to 28.522 
hkl range 
-15 ← h ← 16 
-16 ← k ← 15 
-19 ← l  ← 18 
-18 ← h ← 18 
-22 ← k ← 22 
-27 ← l  ← 26 
-39 ← h ← 38 
-21 ← k ← 22 
-13 ← l  ← 13 
-14 ← h ← 14 
-18 ← k ← 19 
-20 ← l  ← 20 
Reflections collected 30334 66135 65161 30595 
Independent reflections 9763 20347 11131 10379 
Rint 0.0340 0.0724 0.0690 0.0485 
Completeness to θfull (%) 99.5 99.8 99.7 99.3 
Absorption correction type Multi-scan Semi-empirical from equivalents Gaussian Multi-scan 
Tmax and Tmin 1.000 and 0.885 1.000 and 0.520 0.949 and 0.883 1.000 and 0.707 
Data/restraints/parameters 9763 / 0 / 519 20347 / 0 / 1087 11131 / 0 / 558 10379 / 0 / 537 
Goodness of fit F2 1.049 1.035 1.188 1.047 
R1, wR2 [I>2σ(I)]  
 0.0376, 0.0912 0.0628, 0.1429 0.0749, 0.1677 0.0671, 0.1809 
R1, wR2 (all data)  
 
0.0508, 0.1002 0.1129, 0.1759 0.0959, 0.1762 0.0886, 0.2006 
Largest diff. peak and hole (e Å-3) 1.134, -1.038 1.847, -1.432 1.660, -0.707 3.013, -1.694 
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Table S2. Comparison of 1H NMR data for: starting complex 1 ({[Ru(η6-p-cymene)Cl]2(μ-Cl)2}), phosphanes 
PCp (PPh2Cp), PSf (PPh2Sf), PLm (PPh2Lm), PNr (PPh2Nr) and obtained coordination compounds RuPCp 
([Ru(η6-p-cymene)(PCp)Cl2]), RuPSf ([Ru(η6-p-cymene)(PSf)Cl2]), RuPLm ([Ru(η6-p-cymene)(PLm)Cl2]), 
RuPNr ([Ru(η6-p-cymene)(PNr)Cl2]) 
 DRu PCp 2 PSf 1  PLm 3 PNr 4 RuPCp RuPSf 
Atom 
δ [ppm] 
(int.) 
mult. 
J [Hz] 
δ [ppm] 
(int.) 
mult. 
J [Hz] 
δ [ppm] 
(int.) 
mult. 
J [Hz] 
δ [ppm] 
(int.) 
mult. 
J [Hz] 
δ [ppm] 
(int.) 
mult. 
J [Hz] 
δ [ppm] 
(int.) 
mult. 
J [Hz] 
δ [ppm] 
(int.) 
1H NMR 
H1, 3 
1.22 
(12H) 
d 
J = 6.9 
– – – – – – – – 0.88 
(6H) 
d 
J = 6.8 
0.96 
(6H) 
H2 
2.87 
(2H) 
spt 
J = 7.0 
– – – – – – – – 2.47 
(1H) 
spt 
J = 6.9 
2.48 
(1H) 
H5, 9 
5.42 
(4H) 
d 
J = 5.9 
– – – – – – – – 5.26 
(2H) 
d 
J = 5.9 5.15 
(4H) 
H6, 8 
5.29 
(4H) 
d 
J = 5.9 
– – – – – – – – 5.13 
(2H) 
d 
J = 5.7 
H10 
2.10 
(6H) 
s – – – – – – – – 1.84 
(3H) 
s 
1.78 
(3H) 
H11 – – 3.29 d J = 2.9 3.93 bs 
2.80 
(2H) 
bs 3.29 
d 
J = 2.8 
3.89 
(2H) 
s 
4.05 
(2H) 
H12, 15 – – 3.37 – 3.20 m 
2.95- 
3.45 
– 
3.36 m 
2.92 
(4H) 
bs 
2.29 
(2H) 
H13, 14 – – 2.90 – 3.93 m 2.89 m 2.28 (4H) bs 
2.76, 2.95 
(2H, 2H) 
H16 – – – – 0.94 d 
J = 5.9 
0.97 
(3H) 
d 
J = 5.7 
– – – – 0.89 
(3H) 
H17 – – – – – – – – – – 
H42 – – 
7.34- 
7.47 
– 7.29- 
7.65 
– 
7.03- 
7.60 
(12H) 
– 7.33- 
7.46 
– 
7.97- 
8.13 
(4H) 
m 
7.98- 
8.17 
(4H) 
H43, 44 – – 
7.41- 
7.62 
(6H) 
m 
7.40- 
7.60 
(6H) 
H63 – – 7.95 d 
J = 13.8 
6.46 
bs 
(-NH2) 
7.84 
(1H) 
d 
J = 11.4 
7.95 
d 
J = 13.0 
7.89 
(1H) 
d 
J = 13.3 
6.39 
(2H) 
H67 – – 8.71 s 8.62 s 8.52 (1H) S 8.63 s 
8.70 
(1H) 
s 
8.60 
(1H) 
H69 – – 7.34- 7.47 – – – – – 6.82 
d 
J = 6.8 
7.13 
(1H) 
d 
J = 7.1 
– 
H70 – – 15.01 s 14.54 bs 14.65 (1H) bs 15.13 bs 
14.99 
(1H) 
s 
14.61 
(1H) 
H71 – – 3.53 m 3.93 bs 4.39 
(2H) 
d 
J = 3.6 
4.31 m 
3.46 
(1H) 
bs 
3.85 
(1H) 
H72 – – 1.18 m 1.07- 
1.21 
m 
1.48 
(3H) 
t 
J = 3.7 
1.56 m 
1.05- 
1.40 
(4H) 
m 
1.02- 
1.27 
(4H) H73 – – – – – – 
31P{1H} NMR 
P1 – – -27.4 s -35.9 s -28.8 s -27.5 s 27.0 s 25.7 
δ – chemical shift, int. – intensity of signal, J – coupuling constant, mult. – multiplicity: s – singlet, d – doublet, t 
– triplet, q – quartet, spt – septet, m – multiplet, b – broad 
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Fig. S1 Crystal structure of complex RuPSf with indicated Ru1-C70 distances. 
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Fig. S2 +ESI mass spectrum of complex RuPCp. 
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Fig. S3 +ESI mass spectrum of complex RuPSf. 
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Fig. S4 +ESI mass spectrum of complex RuPLm. 
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Fig. S5 +ESI mass spectrum of complex RuPNr. 
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Fig. S6 CV voltammograms for ferrocene in DMF in the range of potentials from -0.2 V to 
0.5 V. Scan rate: 10 mV s-1. 
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Fig. S7 Cyclic voltammograms of PCp, PSpf, PLm, and PNr in DMF (5 mM). Scan rate: 
100 mV/s. The potentials were referenced to the Fc0/+ redox couple. 
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Fig. S8 Selected UV-vis spectra before and after CV experiment for RuPCp and RuPSf 
ruthenium(II) complexes. 
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Fig. S9 UV-vis spectra of studied ruthenium(II) complexes in dimethylformamide (DMF) 
recorded during 24 hours at 25ºC. 
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Fig. S10 Dependency of fluorescence intensities ratios on time at the emission wavelength of 
605 nm, in the presence (I) and absence (I0) of the tested ligand (A), and Ru(II) compounds 
(B) in a system with CT-DNA-EB. 
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Fig. S11 Circular dichroism spectra of studied arene Ru(II) compounds in a system with CT-
DNA. 
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HIGHLITHS 
? Half-sandwich Ru(II) complexes with phosphanes derived from fluoroloquinolones 
are synthesized 
? Half-sandwich Ru(II) complexes intercalate with DNA not causing conformation 
changes 
? Half-sandwich Ru(II) complexes cause cleavage of a single DNA strand 
? Polymeric micelles loaded with Ru(II) complexes enable efficient complex 
accumulation inside cancer cells 
? Polymeric micelles loaded with Ru(II) complexes exhibit promising anticancer 
activity in vitro 
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